Solange Peters to Disease-Free Survival
This is a "connection" page, showing publications Solange Peters has written about Disease-Free Survival.
Connection Strength
0.145
-
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017 08 31; 377(9):829-838.
Score: 0.116
-
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med. 2017 05; 5(5):435-444.
Score: 0.029